Skip to main content

Table 2 Baseline characteristics of patients treated with pemetrexed-containing chemotherapy

From: Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

Clinical characteristics

HER2

EGFR

ALK/ROS1

KRAS

P value

N

25

74

39

40

 

Age, years (median,range)

55(44–77)

58(27–80)

54(37–77)

64.5(33–80)

0.002

  < 65

21(84.0%)

55(74.3%)

28(71.8%)

20(50.0%)

 

  ≥ 65

4(16.0%)

19(25.7%)

11(28.2%)

20(50.0%)

 

Gender

 Male

12(48.0%)

37(50.0%)

20(51.3%)

33(82.5%)

0.004

 Female

13(52.0%)

37(50.0%)

19(48.7%)

7(17.5%)

 

Smoking status

 Non-smoker

18(72.0%)

56(75.7%)

29(74.4%)

15(37.5%)

<0.001

 Smoker

7(28.0%)

18(24.3%)

10(25.6%)

25(62.5%)

 

PS

 0–1

22(88.0%)

68(91.9%)

36(92.3%)

32(80.0%)

0.269

  ≥ 2

3(12.0%)

6(8.1%)

3(7.7%%)

8(20.0%)

 

Therapy

 Monotherapy

4(16.0%)

9(12.2%)

3(7.7%)

9(22.5%)

0.570

 Plus carboplatin

14(56.0%)

42(56.8%)

24(61.5%)

23(57.5%)

 

 Plus cisplatin

7(28.0%)

23(31.1%)

12(30.8%)

8(20.0%)

 

 Maintenance therapy

7(28.0%)

18(24.3%)

13(33.3%)

5(12.5%)

0.175

 No maintenance

18(72.0%)

56(75.7%)

26(66.7%)

35(87.5%)